Global Newcastle Disease Vaccine Market Size, Share, Growth Analysis Report - Forecast 2034

Newcastle Disease Vaccine Market: Industry Perspective

The global newcastle disease vaccine market size was worth around USD 348.56 Million in 2024 and is predicted to grow to around USD 541.3 Million by 2034 with a compound annual growth rate (CAGR) of roughly 4.5% between 2025 and 2034. The report analyzes the global newcastle disease vaccine market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the newcastle disease vaccine industry.

Request Free Sample

Newcastle Disease Vaccine Market: Overview

Newcastle disease is an infectious disease that affects many avian species, both domestic and wild; it is transmissible to humans. There are several Newcastle disease vaccines available on the market that are suitable for commercial chickens. The I-2 Newcastle disease vaccine (Thermostable Vaccine) has been produced for local or regional development and to combat Newcastle disease in village chicken. After storage for one to two hours at room temperature, several Newcastle disease vaccinations worsen. This renders them unfit for use in villages where the vaccine will need to be transported at room temperature for hours or, in some cases, days. The I-2 vaccine also needs long-term storage in cold temperature, but the vaccine will not deteriorate as easily as conventional vaccines when the vaccine is delivered to the field.

Key Insights

• As per the analysis shared by our research analyst, the global newcastle disease vaccine market is estimated to grow annually at a CAGR of around 4.5% over the forecast period (2025-2034).
• Regarding revenue, the global newcastle disease vaccine market size was valued at around USD 348.56 Million in 2024 and is projected to reach USD 541.3 Million by 2034.
• The newcastle disease vaccine market is projected to grow at a significant rate due to increasing global demand for poultry products, the growing incidence of Newcastle disease outbreaks and associated economic losses, rising awareness among farmers about the benefits of vaccination and biosecurity, and continuous advancements in vaccine technology.
• Based on Vaccine Type, the Live Attenuated segment is expected to lead the global market.
• On the basis of Species, the Chicken segment is growing at a high rate and will continue to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

Newcastle Disease Vaccine Market: Growth Factors

Increasing need to control disease outbreaks to drive industry expansion

Raising vaccines to curb outbreaks of avian disease and increasing demand for food items linked to poultry are mainly driving the global Newcastle disease vaccine market. In addition, the market is driven by growing awareness among veterinary practitioners about animal vaccination, increasing meat consumption, and rising government food safety initiatives. For example, according to the Middle East Rating Agency, the Qatar government established central food laboratories in April 2019 with various food safety procedures and analyses to ensure that consumers are delivered contamination-free, healthy, and high-quality meat products.

The growing population of poultry is also driving the Newcastle disease vaccine market demand for products. Consumption of contaminated meat threatens human health, making it imperative that birds are vaccinated prior to use. The rapid spread of illnesses and the lack of treatment options are the key challenges faced by poultry farms. Vaccination is necessary to avoid such situations. Compulsory vaccination of other domesticated & agricultural animals, increased inventories of poultry, improved productivity of livestock, and an increased emphasis on food safety contribute significantly to market growth.

Newcastle Disease Vaccine Market: Restraints

High cost of vaccine development and limited availability of skilled professionals might restrict market growth

The global Newcastle Disease Vaccine Market faces several restraints that could hinder its growth in the coming years. One of the major restraints is the high cost of vaccine development, which may discourage new players from entering the market. Another key restraint is the stringent regulations governing the development, production, and distribution of vaccines, which can delay the approval and commercialization of new vaccines. Additionally, the limited availability of skilled personnel and infrastructure in certain regions may hamper the growth of the market. Finally, the presence of alternative treatments and preventive measures, such as biosecurity measures and dietary supplements, may reduce the demand for Newcastle disease vaccines, particularly in regions with limited resources.

Newcastle Disease Vaccine Market: Opportunities

Introduction of new, advanced, and improved vaccines create ample opportunities for the market

The Newcastle disease vaccine industry offers several opportunities that could drive its growth in the coming years. One of the major opportunities is the increasing prevalence of the Newcastle disease in poultry, which is driving the demand for effective and safe vaccines globally. Another key opportunity is the growing awareness of the benefits of vaccination among farmers, veterinarians, and poultry producers, which is increasing the uptake of Newcastle disease vaccines. Additionally, the introduction of new and advanced vaccines that offer improved efficacy, safety, and convenience is expected to further fuel the growth of the market. Finally, the increasing investments by governments and private organizations in animal health and welfare, particularly in emerging economies, are expected to create new opportunities for market players to expand their reach and market share.

Newcastle Disease Vaccine Market: Challenges

Limited access to new, improved vaccines and emergence of new strains might act as a challenge

The Newcastle disease vaccine industry faces several challenges that could hinder its growth and development in the coming years. One of the major challenges is the emergence of new and more virulent strains of the Newcastle disease virus, which could render existing vaccines ineffective and increase the need for more advanced and effective vaccines. Another key challenge is the limited access to vaccines in certain regions, particularly in developing countries with limited resources and infrastructure.

Newcastle Disease Vaccine Market: Segmentation

The global Newcastle disease vaccine market is segmented based on vaccine type, species, and region.

Based on Vaccine Type, the market is bifurcated into Live Attenuated, Inactivated, and Thermostable. The live attenuated vaccine segment held the largest market share in 2024 and is further predicted to cite the fastest CAGR during the forecast period. Live Attenuated Vaccines (LAV) have been widely used and preferred over other vaccine types due to their effectiveness, low cost, and ability to provide long-lasting immunity. LAVs have been shown to confer broad-spectrum immunity against different strains of Newcastle disease viruses, making them a popular choice among poultry farmers. These factors drive the growth of the segment during the forecast period.

Based on Species, the market is segmented based on chicken, duck, goose, And others. The chicken segment held the dominating market share in 2024 and is further expected to occupy a significant CAGR during the forecast period. Newcastle Disease Virus (NDV) is a significant threat to the chicken industry, leading to significant economic losses due to high mortality rates and reduced egg production. Therefore, the demand for Newcastle Disease Vaccines is high among chicken farmers, making this segment the most profitable in the market. However, vaccines for other bird species such as ducks and geese are also in demand, especially in regions where these birds are raised commercially or for domestic purposes.

Recent Developments

• In 2021, Elanco Animal Health, an American Pharmaceutical company announced that it had completed the acquisition of Kindred Biosciences, a biopharmaceutical company focused on developing vaccines for pets and livestock. The acquisition included Kindred's Newcastle Disease Virus Vectored vaccine platform, which uses a viral vector to deliver antigens to animals and trigger an immune response. This acquisition will help Elanco to expand its presence in the poultry vaccine market and develop new vaccines for poultry and other animal species.
• In 2020, Merial Animal Health, a multinational animal health company, announced that it had received approval from the European Medicines Agency for a new inactivated vaccine, Vaxxitek® ND-IBD. The vaccine provides protection against both Newcastle Disease and Infectious Bursal Disease in chickens, and its innovative formulation reduces the risk of vaccine reactions.

Newcastle Disease Vaccine Market: Report Scope

Newcastle Disease Vaccine Market: Regional Analysis

North America to rule the global market in terms of market share

Due to increased consumption of poultry-related food items, consumer perception of food safety, and a high incidence of avian diseases, North America has dominated the global Newcastle disease vaccine market and is expected to sustain its lead over the forecast period. In addition, the booming production of poultry meat has played a key role in the region's dominance. According to the United Nations Food and Agriculture Organization (UNFAO), the U.S. is the world's largest producer of poultry meat, accounting for 18.0 percent of total production. Furthermore, the adoption of poultry vaccines in the country is being driven by joint strategic projects and acquisitions to further foster better avian health. Market development is also being fueled by increased investment in animal welfare and favorable reimbursement policies.

The European market is expected to emerge as a strong contender because of government measures for research & development activities and rapid progress in animal husbandry practices.

The Asia Pacific market is expected to report the fastest growth rate over the forecast period, due to growing awareness of poultry vaccines and the increase in the number of vaccination awareness programs in the region.

Newcastle Disease Vaccine Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the newcastle disease vaccine market on a global and regional basis.

The global newcastle disease vaccine market is dominated by players like:

• Merial
• QYH Biotech
• CEVA
• Yebio
• Ringpu (Tianjin) Bio-Pharmacy Co. Ltd
• Bayer AG
• Hipra
• Anicon Labor GmbH
• Chengdu Tech-bank Biological Products Co. Ltd.
• Ringpu Bio-Technology Co. Ltd.
• MSD Animal Health
• Nisseiken Co.
• Harbin Veterinary Research Institute
• Merck Animal Health
• ChengDu Tecbond
• DHN
• Zoetis
• Elanco (Lohmann)
• CAVAC
• Vaksindo
• FATRO

The global newcastle disease vaccine market is segmented as follows;

By Vaccine Type

• Live Attenuated
• Inactivated
• Thermostable

By Species

• Chicken
• Duck
• Goose

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America